Viewing nowCombinationOlodipine Tablet 5/40 Milligrams (Amlodipine, Olmesartan Medoxomil)
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Kyungdong Pharmaceutical Co., Ltd.

MFDS item code 201404739 · Approved 2014.10.15 · Insurance code 648103500
Treatment of essential hypertension not controlled with monotherapy
This medication is used to effectively lower blood pressure in patients with essential hypertension whose blood pressure is not sufficiently controlled by monotherapy with amlodipine or olmesartan medoxomil.
Take 1 tablet once daily with water, with or without food. It is recommended to take the tablet at the same time each day, if possible (e.g., in the morning). Before starting this drug, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg as monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg as monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ○ Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ○ Patients with hepatic impairment: Caution should be exercised when administering this drug to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This drug should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this drug, under Precautions for Use.) ○ Older adults: In general, treatment should be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in older adults.
○ Pediatric patients: The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately if pregnancy is confirmed. It should not be administered to patients with hypersensitivity to any of its components, those who are pregnant or breastfeeding, those with severe liver dysfunction or aortic stenosis, those with biliary obstruction, patients undergoing kidney dialysis, those in shock, and certain diabetic patients. Patients with fluid or salt depletion may experience low blood pressure when this medication is initially administered, so it should be administered with caution. This medication has a vasodilatory effect and should be used carefully in patients with severe aortic stenosis, obstructive coronary artery disease, and congestive heart failure. Patients with impaired renal function may experience worsening kidney function after starting this medication, so renal function should be monitored regularly. Patients with decreased liver function should also use this medication with caution and may require dosage adjustments depending on their liver function status. Side effects such as dizziness, headache, hypotension, edema, dyspepsia, and rash may occur, and if any unusual symptoms arise, they should consult a healthcare professional. Women who are pregnant or planning to become pregnant are advised to use alternative treatments that are confirmed to be safe instead of this medication. Breastfeeding women should stop breastfeeding or discontinue this medication, as it may be transferred to breast milk and affect the infant. The safety and efficacy of this medication have not been established in children under 18 years of age, and its use is not recommended. Elderly patients should start at a lower dose considering potential declines in liver, kidney, and heart function and comorbidities, and should be monitored closely. In cases of overdose, symptoms such as hypotension and increased heart rate may occur, and immediate medical attention should be sought. This medication should be stored in a tightly closed container to protect it from direct sunlight and humidity, and kept out of reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. It is best maintained at room temperature between 1 to 30 degrees Celsius.
Light yellow, round, film-coated tablets
30 tablets/Alu-Alu [10 tablets/Alu-Alu x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Kyungdong Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.